PT-141 + Oxytocin
Compounded intranasal combination of bremelanotide and oxytocin. The combination itself has not been studied.
Not FDA-approved. Compounded combination; not approved in any jurisdiction. This page describes research and public discussion; it is not a recommendation to use.
Overview
This blend pairs a melanocortin agonist with oxytocin. Each ingredient has its own evidence base (see component profiles), but no clinical trial has tested them together.
Blend components
Mechanism of action
Combines MC4R-mediated desire signaling with oxytocin receptor activity.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
No studied combination dose D Anecdotal / community | Varies by compounder | As needed | — | Intranasal |
Clinical trials & studies
No studies of this specific combination have been published.
Safety
Side effects
- Sum of component risks: nausea, flushing, BP elevation, headache
Contraindications
- Uncontrolled hypertension
- Pregnancy
Interactions
- Naltrexone (with bremelanotide)
Long-term safety
Unknown.
Regulatory status
Unapproved / research
Compounded combination; not approved in any jurisdiction.